WAVE Life Sciences (WVE) Misses Q4 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LVS
9. LRCX
10. MRK

Go back to WAVE Life Sciences (WVE) Misses Q4 EPS by 6c

Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 22, 2023 7:30 AM EDT

Achieved clinical validation of PRISM platform in 2022 demonstrated ability to potently and durably engage RNA targets and translate preclinical data to the clinic         

Extended leadership in RNA editing and advanced WVE-006 for AATD first-in-class RNA editing candidate transitioning to clinical development in 2023

Initiating Part B of WVE-N531 study in exon 53-amenable DMD to assess dystrophin after 24 and 48 weeks of biweekly dosing

Strategic collaboration with GSK underway, expected to add multiple first-in-class discovery programs to Wave pipeline, including RNA editing and RNAi programs, as well as potential for up... More